Pursuing bold technology is in our DNA.
BrainChild Bio is leveraging years of experience in cell engineering and drug discovery to become a first mover in the CNS-oncology immunotherapy sector. We are integrating advanced-stage synthetic technologies into our therapeutic platform to overcome the challenges of solid tumor targeting within the central nervous system.
Targeted, potent and persistent.
We are pioneering cell therapy for CNS diseases through repetitive dosing directly to the cerebroventricular space bypassing the blood-brain barrier. This allows for augmented tumor access and compartmentalization of therapeutic cells for enhanced safety and efficacy, eliminating the need for systemic lymphodepleting chemotherapy.
Our recursive dosing strategy, grounded in traditional dosing principles, is designed to minimize toxicity while enhancing and sustaining potency, ensuring a continuous and controlled presence of bioactive, anti-tumor effector cells in the tumor bed.
Engineered functionality. Integrated by design.
Multiplexed Targeting
To overcome tumor target gene expression heterogeneity, we have a portfolio of high-value CARs targeting primary brain tumors and brain metastases, each of which have been tested in Phase I trials with excellent safety and tolerability outcomes. These targets include oncogenic EGFR, HER2, B7-H3 and IL13Ralpha2. Our portfolio is actively being investigated clinically as multiplexed targeting products as a strategy to diminish the incidence of therapeutic failures arising from the outgrowth of antigen escape tumor variants.
Potency Enhancement
Tumors that arise in or metastasize to the CNS deploy immuno-evasive mechanisms that diminish the activity of immune effector cells. We have developed a library of synthetic transgenes that, when expressed alongside CARs, augment the potency of the manufactured cell product and counteract the immunosuppressive impact of the tumor microenvironment. Our lead candidate PotencyPlus transgene will be integrated into BCB-214 for near-term Phase I testing.
Our initial clinical focus is on diffuse intrinsic pontine glioma (DIPG), an incurable type of childhood cancer that forms in the brainstem — with plans to expand to other pediatric and adult brain tumors, including glioblastoma and brain metastases.
Brain tumors are the most common solid cancer in children and the leading cause of childhood cancer-related deaths.
Glioblastoma affects nearly
Americans every year and is incurable.
Metastasis to the brain will occur in approximately
cancer patients.